LDS/Medical Tests/Primidone, Urine

Primidone, Urine

Primidone is classified as an anticonvulsant drug and used to treat epileptic seizures. Primidone belongs to the pyrimidinedione class of drugs. The class of drugs known as anticonvulsants are designed to help the physician in treating patients with seizures. The most common type of seizure that the physician encounters in clinical medicine are epileptic seizures. Epilepsy is a disease of the brain in which an individual experiences recurrent seizures. Children may develop seizures as a result of a fever, known as febrile seizures.

The specific type of seizure that primidone is used to treat are termed partial seizures. Primidone is metabolized in the liver to the major metabolite, phenylethylmalonamide (PEMA) and phenobarbitol, both are pharmacologically active. Primidone has a much shorter half-life than either of its metabolites: 3-23 hours.

As with most therapeutic drugs, primidone is extensively metabolized in the liver but absorbed mainly in the small intestine. The route of administration of primidone is orally. Overdose effects include shallow respiration, clammy skin, dilated pupils, weak and rapid pulse, coma, and possible death. Primidone can be analyzed by a variety of analytical methods such as Gas Chromatography/Mass spectroscopy (GC/MS), Liquid Chromatography/Mass Spectroscopy (LC/MS), Immunoassay, and screening spot testing.

  • Therapeutic monitoring
  • Drug abuse evaluation
  • Toxicity assessment
  • Patient compliance
A qualitative positive result from an immunoassay type test indicates only the presence of primidone and does not necessarily correlate with the extent of physiological and psychological effects. Any positive result should be confirmed by a non-immunological method such as GC, LC/MS or GC/MS.

Therapeutic level: 5-12 mg/L
Toxic level: >15 mg/L

Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses.    

Cut-Off Ranges
Cut-off values can vary based on the particular method of analysis that is used for detection by a quantitative method, such as LC/MS or GC/MS. The testing laboratory cut-off range is listed on the patient report. Consult your physician for further information or click on one of the references that are listed below.

Liquid Chromatography/Mass Spectroscopy (LC/MS) or Gas Chromatography/Mass Spectroscopy (GC/MS). The preferred method of detection is LC/MS. The main method of quantitation detection is via LC/MS or LC/MS/MS (liquid chromatography coupled with mass spectroscopy).

Urine collected in a sterile urine cup. 

Stability

  • Ambient: 3-5 days
  • Refrigerated: 5-7 days
  • Frozen: 30 days
Pharmacogenetic testing such as genotyping for *CYP3A4, CYP3A5, CYP2D6, CYP2C9, CYP2C19,* COMT and *OPRM1* variants could guide drug and dose selection. Supportive testing such as a liver profile, kidney profile, comprehensive metabolic panel, CBC, and testing for concomitant drugs may be appropriate.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Baselt RC (ed). Analytical procedures for therapeutic drug monitoring and emergency toxicology, 2nd ed. Lettleton, MA: PSG Publisging Co.; 1987
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 9th ed. Seal Beach, CA: Biomedical Publications; 2011.
  • Baselt RC (ed). Analytical procedures for therapeutic drug monitoring and emergency toxicology, 2nd ed. Littleton, MA: PSG Publishing Co.; 1987.
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 6th ed. Foster City, CA: Biomedical Publications; 2002.
  • Gupta RN. Review: drug level monitoring: sedative hypnotics. J Chromatogr. 1985;340:139-72.
  • Levine B (ed). Principles of Forensic Toxicology, 4th ed. Washington DC: AACC Press. Chapter 22, Anticonvulants and Antiarrhythmics, pp. 391-402; 2013.